In a report released today, Leah R. Cann from Oppenheimer maintained a Hold rating on Agios Pharma (NASDAQ: AGIO). The company’s shares closed on Friday at $96.86, close to its 52-week high of $97.59.
Cann noted:
“AG-881 is a promising early stage molecule. We have not included any impact from AG-881 in our outlook through 2022. The early data presented, especially in the non- enhancing mutant glioma population, are highly encouraging. Based on investigator discussions at ASCO, we believe a number of questions still need to be answered on the role of IDH 1/2 inhibition in gliomas, and on a development path for AG-881 in this setting.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 20.0% and a 62.3% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $108.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $97.59 and a one-year low of $47.25. Currently, Agios Pharma has an average volume of 369.5K.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
